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SUMMARY

Post-translational addition of amino acids to proteins by enzymes using aminoacyl-tRNA is an emerging regulatory mechanism. Examples include Arg transfer
in eukaryotes, Leu/Phe transfer in bacteria, and tRNA-synthetase-mediated addition of amino acids to Lys side chains. Here, we present a method of purification
and use of tRNA for such reactions, focusing on tRNAArg and its use for arginylation. This method can also be used for other tRNA-mediated reactions.
For complete details on the use and execution of this protocol, please refer to
Avcilar-Kucukgoze et al. (2020)
BEFORE YOU BEGIN
Design tDNA Oligonucleotides for tRNA Transcription
Timing: 2–3 h
1. Design tDNA oligonucleotides with the T7 promoter.
Note: Two single-stranded tDNA oligonucleotides are designed to cover the entire sequence
of the tRNA of interest. One of the two tDNA oligonucleotides encodes the 50 -end sequence
of the sense strand, while the other encodes the 30 -end sequence of the anti-sense strand. The
two oligonucleotides of the opposite polarity overlap in the middle of the tRNA sequence for
25 nucleotides, which, upon annealing, provide the template for synthesis of the doublestranded tRNA sequence that can be transcribed by T7 RNA polymerase (RNAP). The
oligonucleotide encoding the 50 -end sequence of the sense strand includes an upstream T7
promoter sequence, which has the minimal sequence of 50 -TAATACGACTCACTATAG-30 .
The underlined G is the first nucleotide to be incorporated into the transcribed tRNA, which
should be followed by another G for high efficiency of transcription. The sequence of tRNA
genes is obtained from Genomic tRNA Database (http://gtrnadb.ucsc.edu/) (Chan and
Lowe, 2016). The oligonucleotide encoding the 30 -end sequence of the anti-sense strand
should include the 30 CCA tail, which is not encoded in eukaryotic tRNA gene.
2. An example of tDNA oligonucleotides for mouse tRNAArgACG:
a) Full-length tRNAArgACG: 50 -GGGCCAGTGGCGCAATGGATAACGCGTCTGACTACGGATC
AGAAGATTCCAGGTTCGACTCCTGGCTGGCTCGcca-30 , where the anticodon ACG is
underlined

STAR Protocols 1, 100207, December 18, 2020 ª 2020 The Authors.
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b) + T7 promoter: TAATACGACTCACTATAGGGCCAGTGGCGCAATGGATAACGCGTCTGA
CTACGGATCAGAAGATTCCAGGTTCGACTCCTGGCTGGCTCGcca
c) Forward tDNA oligonucleotide: 50 -TAATACGACTCACTATAGGGCCAGTGGCGCAATGGA
TAACGCGTCTGACTACGGATCA-30
d) Reverse tDNA oligonucleotide: 50 -TGGCGAGCCAGCCAGGAGTCGAACCTGGAATCTTCT
GATCCGTAGTCAGACGCGTTATCC-30

KEY RESOURCES TABLE

REAGENT or RESOURCE

SOURCE

IDENTIFIER

Promega

Cat# L2005

Tris base

Fisher Scientific

Cat# BP152-1

dNTP mix (10 mM)

Invitrogen

Cat# 18427088

Bacterial and Virus Strains
E. coli JM109
Chemicals, Peptides, and Recombinant Proteins

DNA polymerase I, Large (Klenow) Fragment

New England Biolabs

Cat# M0210S

103 NEB Buffer 2

New England Biolabs

Cat# B7002S

KOAc potassium acetate

Fisher Scientific

Cat# BP364-500

KCl

Fisher Scientific

Cat# BP366-500

Phenol/chloroform/isoamyl alcohol

Fisher Scientific

Cat# BP1752I-100

Ampicillin

Fisher Scientific

Cat# BP1760-25

LB, Lennox

BD Biosciences

Cat# 240230

IPTG

LabScientific

Cat# I-555

EDTA

Fisher Scientific

Cat# BP120-500

NaOAc

Sigma-Aldrich

Cat# S-2889

MgOAc

Fisher Scientific

Cat# BP215-500

Phenol, saturated, pH 4.5 (acidic phenol)

VWR Scientific

Cat# 97064-716

NaCl

Sigma-Aldrich

Cat# S6191

L-[2,3,4-3H]-Arg

PerkinElmer

Cat# NET1123001MC

L-[14C(U)]-Arg

Moravek Biochemicals

Cat# MC137

13

L-[ C,

15

Pierce Chemical

Cat# 89990

ATP

N]-Arg

Fisher Scientific

Cat# BP413-25

HEPES

Fisher Scientific

Cat# BP310-100

MgCl2 hexahydrate

Fluka

Cat# 63068

DTT

Fisher Scientific

Cat# BP172-5

Chloroform

Fisher Scientific

Cat# BP1145-1

Acetonitrile

Sigma-Aldrich

Cat# 34998

TFA

Sigma-Aldrich

Cat# T6508

Sybr Gold

Invitrogen

Cat# S11494

Ethanol

Decon Laboratories

Cat# 2716

Isopropanol

Sigma-Aldrich

Cat# I9030

Aminoacyl-tRNA synthetase mix

Sigma-Aldrich

Cat# A3646

Recombinant mouse ATE1

Wang et al., 2019

N/A

Recombinant human RARS

Wang et al., 2019

N/A

Recombinant human RNase T2

Thorn et al., 2012

N/A
(Continued on next page)
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Continued
REAGENT or RESOURCE

SOURCE

IDENTIFIER

Angiotensin II (DRVYIHPF) (Custom
synthetized peptide can be also used)

Sigma-Aldrich

Cat# A9525

DEPC

Sigma-Aldrich

Cat# D5758

Low range ssRNA ladder

New England Biolabs

Cat# N0364S

Megashortscript Kit

Invitrogen

Cat# AM1354

Monarch RNA Cleanup Kit

New England Biolabs

Cat# T2040S

Forward tDNA oligonucleotide:
50 -TAATACGACTCACTATAGGGCCAG
TGGCGCAATGGATAACGCGTCTGAC
TACGGATCA-30

This paper

N/A

Reverse tDNA oligonucleotide:
50 -TGGCGAGCCAGCCAGGAGTCGAA
CCTGGAATCTTCTGATCCGTAGTC
AGACGCGTTATCC-30

This paper

N/A

Gamper et al., 2015

N/A

BioRender

BioRender

https://biorender.com

Genomic tRNA Database

Chan and Lowe, 2016

http://gtrnadb.ucsc.edu/

National Diagnostics

Cat# EC-833

Critical Commercial Assays

Oligonucleotides

Recombinant DNA
pKK223-3 tRNAArgACG plasmid
Software and Algorithms

Other
UreaGel System
Ecoscint scintillation counter

National Diagnostics

Cat# LS-271

Autofluor

National Diagnostics

Cat# LS-315

C18 spin column

The Nest Group

Cat# HUM S18V

0.22 mm syringe filter

Millipore

Cat# SLGS0250S

RNaseZap

Ambion

Cat# AM9780

MATERIALS AND EQUIPMENT
Crush and Soak Buffer, pH 7.5
Reagent

Final Concentration

Amount

Potassium acetate (KOAc)

50 mM

0.98 g

KCl

200 mM

2.98 g

DEPC-treated water

Up to 200 mL

Prepare the solution under RNase-free conditions. Adjust pH to 7.5. Aliquot to avoid RNase contamination and store at 20 C for up to a year.
103 Buffer, pH 7.5
Reagent

Final Concentration

Amount

HEPES

500 mM

11.91 g

KCl

250 mM

1.86 g

MgCl2 hexahydrate

150 mM

3.05 g

DTT (added freshly from stock solution on
the day of experiment).

1 mM

1 mL of 100 mM stock solution, stored at
-20 C for up to a year.

DEPC-treated water

Up to 100 mL

STAR Protocols 1, 100207, December 18, 2020
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Figure 1. tRNAArg Preparations Obtained by the Methods Described in Steps 1–30
300 ng of RNA samples was separated on 12% PAGE/7.5 M urea.

Mix all the components except DTT under RNase-free conditions. Adjust pH to 7.5. Aliquot to avoid
RNase contamination and store at 20 C–22 C for up to a month. Add DTT freshly from a frozen stock
to the working aliquot on the day of experiment.

STEP-BY-STEP METHOD DETAILS
tRNA Preparation
Here we present two different methods for tRNA preparation. The first method involves in vitro transcription by T7 RNAP, which efficiently synthesizes the tRNA of interest as a transcript, but lacking all
natural post-transcriptional modifications (Hall et al., 1989; Sampson and Uhlenbeck, 1988; Samuelsson et al., 1988). It allows to produce micrograms of an individual tRNA (see Figure 1, left
lane, for an example). The second method involves the expression of the tRNA of interest in bacteria
and isolation of total tRNA mixture enriched for the expressed tRNA (see Figure 1, right lane, for an
example). This method produces milligrams of total tRNA mixture, containing a major proportion of
the overexpressed tRNA (an estimated 40%–50%). While this purity is sufficient for many applications, the in vitro transcribed tRNA should be used in cases where the use of highly homogeneous
tRNA preparation is important, regardless of the post-transcriptional modifications. Both preparations work well in the case of arginylation.
In Vitro Transcription of Mouse tRNAArg
Timing: 2–3 days
1. To anneal the two single-stranded tDNA oligonucleotides, mix the following: 10 mL of the forward
oligonucleotide (100 mM), 10 mL of the reverse oligonucleotide (100 mM), 4 mL of 200 mM Tris-HCl
(pH 7.5), 16 mL of nuclease-free water.

Reagent

Final Concentration

Amount

Forward oligonucleotide (100 mM)

25 mM

10 mL

Reverse oligonucleotide (100 mM)

25 mM

10 mL

200 mM Tris-HCl (pH 7.5)

20 mM

4 mL

Nuclease-free water

n/a

16 mL

4
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2. Unfold the oligonucleotides by heating for 2 min at 95 C and anneal the overlapping oligonucleotides for 3 min at 20 C–22 C.
3. To fill-in the 50 overhangs and form blunt ends, combine the following, in this order: 20 mL of 103
buffer (NEB Buffer 2), 6.6 mL of 1 mM dNTP mix, 4 mL of DNA polymerase I, Large (Klenow) Fragment (5 U/mL), 129.4 mL of nuclease-free water and 40 mL of the tDNA oligonucleotide mix (from
step 1).

Reagent

Amount

103 buffer (NEB Buffer 2)

20 mL

1 mM dNTP mix

6.6 mL

DNA polymerase I, Large (Klenow) Fragment
(5 U/mL)

4 mL

Nuclease-free water

129.4 mL

tDNA oligonucleotide mix (from step 1)

40 mL

4. Incubate for 15 min at 25 C.
5. Add 1 volume of the crush and soak buffer (50 mM potassium acetate (KOAc), 200 mM KCl, pH
7.5) and 2 volumes of phenol/chloroform/isoamyl alcohol (25:24:1). Vortex 30 s and centrifuge at
21,000 3 g for 5 min at 4 C.
6. Precipitate the aqueous phase with 2.7 volumes of ethanol (100%). Incubate for 30 min at 80 C,
followed by centrifugation at 21,000 3 g for 30 min at 4 C.
7. Air dry the pellet for 5–10 min at 20 C–22 C. Dissolve it into 50 mL of nuclease-free water. Determine the concentration by Nanodrop, and the integrity by 2% agarose gel. Store the synthesized
double-stranded DNA template of the tRNA at 20 C.
8. For in vitro transcription of the tRNA, use Megashortscript Kit with 1 mg of the double-stranded
template DNA according to the manufacturer’s instructions (https://www.thermofisher.com/
order/catalog/product/AM1354). Incubate for 16 h at 37 C.
CRITICAL: The reagents, chemicals, tips, and tubes should be RNase-free. All buffers
should be prepared with DEPC-treated water in RNase-free conditions. Reused plastics
or glassware should be washed with RNaseZap followed by pure water.
To digest the DNA template, add 1 mL of TURBO DNase provided by Megashortscript Kit to the
reaction and mix well. Incubate at 37 C for 15 min.
10. Separate the transcription reaction using 12% PAGE/7.5 M urea. The dimension of the gel
should be 14 by 14 by 0.1 cm. Visualize the synthesized tRNA transcript by Sybr Gold under
UV light and excise the tRNA band. Place the excised gel pieces into a 0.2 mL tube with holes
at the bottom. Holes can be made by a needle. Put the 0.2 mL tube into 1.5 mL tube and centrifuge at 16,100 3 g for 1 min at 20 C–22 C. Remove the 0.2 ml tube. Add 2 volumes of crush and
soak buffer (50 mM KOAc, 200 mM KCl, pH 7.5) to the gel pieces and elute tRNA transcript by
shaking the tube on a rotator for 16 h at 4 C.

9.

Note: tRNAs can be cleaned by Monarch RNA Cleanup Kit according to the manufacturer’s
instructions (https://www.neb.com/protocols/2018/06/28/monarch-rna-cleanup-kit-protocol).
It should be noted that T7 RNAP tends to add one or more nontemplated nucleotides at
the 30 terminus of the transcribed RNA (Krupp, 1988; Milligan et al., 1987). Recovering
tRNA from a gel effectively removes these longer tRNA transcripts, although it is more
time-consuming with a reduction in the yield. To enhance the rate of the correct size
transcribed tRNA in the reaction, modified DNA template with methoxy moieties at the
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ribose C20 position of the penultimate nucleotide of the complementary strand could be used
(Kao et al., 1999).
11. To separate the gel pieces from the buffer containing transcribed tRNA, filter the sample
through a 0.22 mm syringe filter. Add 1 volume of isopropanol and precipitate tRNA for
30 min at 80 C.
12. Pellet tRNA by centrifugation at 21,000 3 g for 30 min at 4 C. Wash the tRNA pellet with 70%
ethanol twice. Dissolve it into DEPC-treated water. Determine the concentration by Nanodrop.
The A260/A280 ratio should be R 2.
13. To ensure correct tRNA folding, unfold the tRNA for 2 min at 95 C, followed by 3 min at 20 C–
22 C. Place the sample for further 5 min at 37 C. Store it at 80 C.
Note: (1) Step 13 should be performed only once. The tRNA sample should be aliquoted and
stored at 80 C to prevent damage during multiple freeze/thaw cycles. (2) Since divalent cations, especially Mg2+, are very effective at stabilizing the tertiary structures of most RNAs (Hall
et al., 1989; Klein et al., 2004; Serebrov et al., 1998), addition of Mg2+ at step 13 may promote
the stability of the correct conformation of tRNA.
Preparation of an Enriched tRNAArg Fraction by E. coli Expression
Timing: 4–5 days
This procedure involves expression of a tRNA-encoding plasmid in E. coli, followed by isolation of
total tRNA. The resulting total E. coli tRNA mixture is greatly enriched for the expressed tRNA
(tRNAArg in the case of arginylation, which constitutes an estimated 40%–50% of the total tRNA in
the preparation). Aminoacylation of this mixture with purified arginyl-tRNA synthetase (RARS) can
be used to estimate the exact fraction of tRNAArg in the mixture. This procedure, described below,
yields an enriched preparation of tRNAArg which is suitable for arginylation reaction regardless of the
presence of other tRNA species. Because of its high yield compared to in vitro transcription, this
preparation is recommended for routine arginylation experiments.
14. We generate an expression plasmid for tRNAArg in the pKK223-3 vector, driven by the strong
pTac promoter. Transform E. coli JM109 cells with the plasmid that harbors E. coli tRNAArgACG
following the manufacturer’s protocol for E. coli JM109 transformation (https://www.promega.
com/products/cloning-and-dna-markers/bacterial-strains-and-competent-cells/pro5_alpha_-jm109-and-hb101-competent-cells/?catNum=L2005).
15. Select transformants for the presence of ampicillin-resistance marker by plating the bacteria on
Luria broth (LB) agar plates containing 100 mg/mL of ampicillin. Pick a single colony and grow it
into 20 mL of LB containing 100 mg/mL of ampicillin for 16 h as the pre-culture.
16. Dilute the pre-culture 1:100 into 1 L LB medium supplemented with 100 mg/mL ampicillin.
17. Continually grow the culture with shaking at 37 C until OD600 reaches 0.4–0.6.
18. Induce tRNAArgACG expression by adding 0.3 mM IPTG. Incubate on a shaker for approximately
10 h at 37 C.
Note: If the tRNA of interest is eukaryotic, it should be noted that expression of a eukaryotic
tRNA in E. coli generates the post-transcriptional modifications provided by E. coli enzymes,
which may not reproduce those found in a eukaryotic host.
19. Collect the cells by centrifuging at 5,000 3 g for 25 min at 4 C. Discard the supernatant.
20. Resuspend the cell pellet into 30 mL of 0.9% NaCl.
21. Collect the cells by centrifuging at 5,000 3 g for 15 min at 4 C. Discard the supernatant.
Optional: Weight the pellet. Typical yield is 3.5–5 g of wet cells for 1 L of culture.
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22. First Extraction: Resuspend the pellet into 18 mL of 50 mM sodium acetate (NaOAc), 10 mM
MgOAc, pH 5.0 and add 17.2 mL of commercial acidic phenol, pH 4.5. Transfer the emulsion
into a 125 mL flask and shake it at 215 rpm for 30 min at 20 C–37 C. Centrifuge at 5,000 3 g
for 15 min at 4 C. Collect the upper aqueous phase by gentle aspiration with a pipette and transfer it to a new tube. Be careful not to take any of the interface.
CRITICAL: The reagents, chemicals, tips, and tubes should be RNase-free. All buffers
should be prepared with DEPC-treated water in RNase-free conditions. Reused plastics
or glassware should be washed with RNaseZap followed by pure water.
23. Second Extraction: Add 14 mL of 50 mM NaOAc, 10 mM MgOAc, pH 5.0 to phenol/interphase, and transfer back into the 125 mL flask. Shake it for 15 min as described in step 22.
Repeat the centrifugation and recovery of the aqueous phase. Combine aqueous phases (approx. 36 mL).
24. Precipitation of total nucleic acids: Add 1.5 mL of 5 M NaCl to the aqueous phases collected in
steps 22 and 23 to the final concentration of 0.2 M NaCl. Add 1 volume of isopropanol. Store
briefly at 20 C–22 C and centrifuge at 14,500 3 g for 15 min at 20 C–22 C. Wash the nucleic
acid pellet with cold 70% ethanol, and air dry for 5–10 min.
25. Removal of rRNA by precipitation (needed because at this step the preparation contains ribosomal RNA): Resuspend the pellet into 10 mL of cold 1 M NaCl by vortexing and/or pipetting.
This process is facilitated by letting the pellet hydrate in 1 M NaCl prior to resuspension. Centrifuge the sample at 9,500 3 g for 20 min at 4 C. Collect the supernatant. Resuspend the pellet
into 5 mL of cold 1 M NaCl and centrifuge it again at 9,500 3 g for 20 min at 4 C. Collect the
supernatant and combine it with the first supernatant (total 15 mL).
Optional: The second extraction is optional. The pellet can be resuspended into 15 mL of cold
1 M NaCl.
26. Precipitation of remaining nucleic acids (including DNA and tRNA): Add 30 mL (2 volumes)
of cold ethanol to the supernatant collected in step 25. Incubate for 30 min at 20 C. Centrifuge at 14,500 3 g for 5 min at 4 C. Wash the pellet with 70% ethanol and air dry for
5–10 min.
27. Removal of DNA by precipitation: Dissolve the pellet into 6 mL of 0.3 M NaOAc, pH 5.0. This
may require heating and swirling at 60 C along with pipetting. Add 3.4 mL of isopropanol
(0.56 volume) to the nucleic acid solution and incubate it for 10 min at 20 C–22 C. Centrifuge
at 14,500 3 g for 5 min at 20 C–22 C. Collect the supernatant.
Note: (1) Dispersion is easier if the pellet is in the NaOAc buffer up to 16 h. (2) If the yield is low,
the pellets from multiple 1-liter cultures can be pooled into 6 mL of 0.3 M NaOAc pH 5.0.
28. Final precipitation of tRNAs: Add 2.3 mL of isopropanol to the supernatant (water:isopropanol
is 1.00:0.95) and incubate it for 30 min at 20 C. Centrifuge the suspension at 14,500 3 g for
15 min at 4 C. The pellet should appear white. Wash the pellet with 70% ethanol and air dry
for 5–10 min. Dissolve the pellet into 500 mL of DEPC-treated water. Do not over-dry the pellet.
Over-dried pellet looks transparent, but not white.
29. Deacylation: Add 35 mL of 1.5 M Tris pH 9.0 and incubate it for 45 min at 37 C. Add 53.5 mL
(0.1 volume) of 3 M NaOAc, pH 5.0 and add 1.6 mL (2.7 volumes) of ethanol (100%). Incubate
for 30 min at 80 C. Centrifuge the suspension at 16,100 3 g for 25 min at 4 C. Wash the
pellet with 70% ethanol and air dry. Dissolve the pellet into 250–300 mL of DEPC-treated water.
30. Quantification: Determine the concentration by Nanodrop. The A260/A280 ratio should be R 2.
Typical yield of total tRNA is 5–20 mg. The tRNA sample at this stage should be aliquoted and
stored at 80 C to prevent damage during multiple freeze/thaw cycles.
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Aminoacylation of tRNAArg
Timing: 3–4 h
This procedure is performed similarly for both the in vitro transcribed tRNAArg and the bacterially
expressed preparation enriched in tRNAArg. Since the enzyme used in this reaction (RARS) is specific
to tRNAArg, the charging should be independent of the presence of other tRNA species in the mix;
however, the expected yield of the charged tRNAArg species would depend on the amount of
tRNAArg. Thus, the procedure below does not distinguish between the tRNA prepared by these
two methods, which are referred to, in both cases, as tRNAArg.
Note: In our experience, while the in vitro transcribed tRNA needs to be refolded prior to
charging with RARS, the tRNA preparation from E. coli is already folded correctly, thus we
do not use a refolding step with this preparation, and have encountered no problems with
RARS charging or arginylation.
31. Prepare a 150 mL reaction by mixing the following: 5.67 mL of tRNAArg (5,200 ng/mL;
211.6 mM; 8 mM final concentration), 4.95 mL of ATP (100 mM; 3.3 mM final concentration), 115 mL of L-[2,3,4-3H]-Arg (18.3 mM; 14 mM final concentration), 9.38 mL of purified
human arginyl-tRNA synthetase (RARS) (1,800 mg/mL; 24 mM; 1.5 mM final concentration),
15 mL of 103 buffer (500 mM HEPES, 250 mM KCl, 150 mM MgCl2, 1 mM DTT, pH 7.5).
At the same time, set up the control reaction containing above components, but no
RARS.

Reagent

Final Concentration

Amount

tRNAArg (5,200 ng/mL; 211.6 mM)

8 mM

5.67 mL

ATP (100 mM)

3.3 mM

4.95 mL

L-[2,3,4-3H]-Arg (18.3 mM)

14 mM

115 mL

Purified human arginyl-tRNA synthetase
(RARS) (1,800 mg/mL; 24 mM)

1.5 mM

9.38 mL

103 buffer

1x

15 mL

CRITICAL: Since the protocol requires to use a radioactive isotope, the sample should be
handled in a hot lab with a proper personal protective equipment, e.g., lab coat, goggles
etc, after step 31.
Note: (1) If cognate aminoacyl-tRNA synthetase is not available, a mixture of cell lysates of
the organism of interest, or a commercial E. coli aminoacyl-tRNA synthetase mix, can be
used in its place. It is best, if possible, to use cognate aminoacyl-tRNA synthetase mix, however, the only alternative that is currently commercially available is a mix of E. coli aminoacyl-tRNA synthetases. Our tests indicate that, despite considerations related to organism
specificity (Liu et al., 2011), E. coli and human aminoacyl-tRNA-synthetases work equally
well with both mouse and E. coli tRNAArg (Avcilar-Kucukgoze et al., 2020). Thus, the commercial alternative appears reasonable in the case of tRNAArg. (2) Purification of recombinant human RARS expressed in E. coli can be found in (Wang et al., 2019). (3) For arginylation detection by methods other than scintillation counting, L-[14C(U)]-Arg or L- [13C, 15N]Arg should be used in place of L-[2,3,4-3H]-Arg for autoradiography and mass spectrometry, respectively. Note that the U in L-[14C(U)]-Arg indicates that all carbons are uniformly
labeled.
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32. Incubate the reaction at 37 C for 2 h. Add a total of 250 mL of a solution containing 100 mM
NaOAc, 1 mM EDTA, pH 4.8 then mix it with 400 mL of freshly prepared acidic phenol/chloroform (5:1). Vortex 30 s and centrifuge at 21,000 3 g for 5 min at 4 C.
Note: It is crucial to keep the aminoacyl-tRNAs (aa-tRNA) in acidic conditions, because the
ester bond between the amino acid and the tRNA is easily hydrolyzed at the physiological pH.
33. Add 0.1 volume of 3 M NaOAc, pH 5.0 to the aqueous phase and precipitate it with 1 volume of
isopropanol. Incubate the precipitation reaction for 30 min at 80 C, followed by centrifugation
at 21,000 3 g for 30 min at 4 C.
34. Wash the aa-tRNA pellet with cold 70% ethanol 2–3 times. Air dry the pellet and dissolve it into
23.5 mL of 10 mM NaOAc, 1 mM EDTA, pH 4.8 to preserve the aminoacyl moiety. The final concentration of aa-tRNA is 1 mg/mL, assuming 80% recovery after phenol/chloroform extraction.
The level of aminoacylation should be directly determined by scintillation counter. Typical yields
of aminoacylation are 20%–30% of tRNAArg. Ideally, use a freshly prepared aa-tRNA for further
steps.
Note: Charging level of tRNA is calculated as follows: (1) Measure the cpm value of 1 mL stock
L-[2,3,4-3H]-Arg. (2) Measure the cpm value of 1 mL of Arg-tRNA (1 mg/mL) at step 34. (3) Calculate the moles of L-[2,3,4-3H]-Arg for 1 mg (40.70 pmol) of Arg-tRNA. (4) Calculate the ratio of
L-[2,3,4-3H]-Arg:tRNA in moles.
Note: An example of calculating the aminoacylation level of tRNAArg:
Stock L-[2,3,4-3H]-Arg: 54.5 Ci/mmol, 1 mCi/mL (1 mCi/mL)
1 mL of stock L-[2,3,4-3H]-Arg gives 825,008 cpm.

1 mCi

825,008 cpm

X

527,503 cpm (for 1 mg of Arg-tRNA
measured by a scintillation counter)

x = 0.63 mCi

54.5 mCi

1 nmol

0.63 mCi

X

x = 0.012 nmol = 12 pmol

1 mg of Arg-tRNA (40.70 pmol) contains 12 pmol of L-[2,3,4-3H]-Arg, thereby aminoacylation level is
29.5% (=12/40.70).
Note: Charged tRNA at this step can be used directly in the arginylation reaction (see below,
step 39). Alternatively, charged tRNA can be further processed by RNase T2 to produce Argcharged tRNAArg-derived fragments (Arg-tRFArg) for the arginylation reaction.
Cleavage of Arg-tRNAArg by RNase T2
Timing: 1–2 h
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Since RNase T2 generates tRF from all tRNAs and is not specific to tRNAArg, both in vitro transcribed
and E. coli expressed preparations can in principle be used in this step. However, in vitro transcribed
tRNA is recommended, given its purity that enables fully controlled conditions of the reaction.
35. Prepare a 200 mL reaction by mixing the following: 20 mL of Arg-tRNAArg (1 mg/mL; 4 mM final concentration), 20 mL of purified recombinant form of human RNase T2 (2.4 ng/mL; 0.24 ng/mL final
concentration), 50 mL of 800 mM NaOAc, pH 4.5, 200 mM NaCl and 110 mL DEPC-treated water.

Reagent

Final Concentration

20 mL

4 mM

20 mL

0.24 ng/mL

NaOAc (800 mM)+ NaCl (200 mM)

50 mL

200 mM NaOAc + 50 mM NaCl

DEPC-treated water

110 mL

n/a

Arg-tRNA

(1 mg/mL; 40.70 mM)

Amount

Purified Recombinant form of human RNase
T2 (2.4 ng/mL)

Arg

Note: It is crucial to keep the reaction in acidic conditions to preserve the aminoacyl group on
the tRNA. Notably, RNase T2 used in this protocol acts better in an acidic pH (Campomenosi
et al., 2006). The detailed purification protocol of recombinant human RNase T2 can be found
in (Thorn et al., 2012).
36. Incubate the reaction for 30 min at 37 C. Add a total of 200 mL of a solution containing 10 mM
NaOAc, 1 mM EDTA, pH 4.8 then mix the reaction with 400 mL of freshly prepared acidic phenol/
chloroform (5:1). Vortex the mixture for 30 s and centrifuge at 21,000 3 g for 5 min at 4 C.
Note: To analyze Arg-tRNAArg-derived fragments (Arg-tRFArg) on a gel, autoradiography can
be used if aminoacylation is performed with L-[14C(U)]-Arg. After incubation, mix the reaction
directly with an acidic 23 RNA loading dye and separate the Arg-tRFArg from Arg-tRNAArg by
an 8% acidic denaturing PAGE/7.5 M urea (8% polyacrylamide, 7.5 M urea, 0.1 M NaOAc/
AcOH pH 5.0). Run the gel at 100–150 V (12 V/cm) in a cold room. Treat the gel with AutoFluor according to the manufacturer’s protocol (https://www.nationaldiagnostics.com/sites/
default/files/autofluor_protocol0812_0.pdf). Dry the gel under a vacuum for 2 h at 80 C.
The gel can be exposed to X-ray films or phosphor screens. Because L-[14C(U)]-Arg is highly
stable, the gel can be stored and re-exposed multiple times without decomposition of the label (see Figure 2 for an example).
37. Add 0.1 volume of 3 M NaOAc, pH 5.0 to the aqueous phase and precipitate it with 1 volume of
isopropanol. Incubate at 80 C for 30 min. Pellet Arg-tRFArg by centrifugation at 21,000 3 g for
30 min at 4 C.
38. Wash the pellet with cold 70% ethanol 2–3 times. Air dry the pellet and dissolve it into 16 mL of
10 mM NaOAc, 1 mM EDTA, pH 4.8. The final concentration of Arg-tRFArg is 40.70 mM, assuming
80% recovery after phenol/chloroform extraction. Ideally, use freshly prepared Arg-tRFArg for
enzymatic reactions.
Using Arg-tRNAArg or Arg-tRFArg in an ATE1-Mediated Reaction with a Peptide Substrate
Timing: 2–3 h
This protocol utilizes Arg-tRNAArg or Arg-tRFArg prepared in the steps above, which can both serve
as Arg donors for arginyltransferase ATE1. The procedure is the same regardless of the source and
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Figure 2. Autogradiography of 14C-Arg-tRNAArg Before (Untreated) and After Treatment with RNase T2 under
Acidic Conditions to Produce 14C-Arg-tRNAArg-Derived Fragments (Arg-tRFsArg)
Time intervals after RNase T2 addition are shown on top (the lane marked -RNase T2 represents 0 time point). Arg
charging is retained by the tRFs after RNase T2 cleavage. Arg-tRFs Arg were separated on 8% acidic denaturing PAGE/
7.5 M urea. Reprinted with permission from Avcilar-Kucukgoze et al. (2020).

purity of tRNA, and thus in the protocol below we denote both the in vitro transcribed and bacterially
expressed preparations as Arg-tRNAArg. Arginylation activity is analyzed by detecting the labeled L[2,3,4-3H]-Arg, which is transferred from Arg-tRNAArg or Arg-tRFArg onto the peptide substrate by
ATE1, using scintillation counting. Alternatively, arginylation can be detected by mass spectrometry; in this case L- [13C, 15N]-Arg should be used, to avoid contamination of the instrument with
the radioactive label. For protein substrates, arginylation can also be detected by gel autoradiography; in this case, L-[14C(U)]-Arg is recommended, as it tends to have stronger and more stable
autoradiography signal. Notably, the arginylation reaction with full-length tRNAArg can also be performed in the presence of RARS, which should provide ongoing supply of newly re-charged ArgtRNAArg and thus may improve the efficiency of the reaction (see Wang et al., 2019).
39. Prepare a 50 mL reaction by mixing the following: 6.25 mL of Arg-tRNAArg or Arg-tRFArg
(40.70 mM; 5 mM final concentration), 2.5 mL of angiotensin II (DRVYIHPF) (300 mM; 15 mM final
concentration), 6.81 mL ATE1 (1,320 mg/mL; 22 mM; 3 mM final concentration), 5 mL of 103 buffer
(500 mM HEPES, 250 mM KCl, 150 mM MgCl2, 1 mM DTT, pH 7.5) and 29.44 mL DEPC-treated
water. In parallel, set up the negative control reaction with the above components, but no ATE1.

Reagent

Final Concentration
5 mM

6.25 mL

15 mM

2.5 mL

Arg-tRNA

or Arg-tRF

Arg

(40.70 mM)

Amount

Angiotensin II (DRVYIHPF) (300 mM)

Arg

ATE1 (1,320 mg/mL; 22 mM)

3 mM

6.81 mL

103 buffer (500 mM HEPES, 250 mM KCl,
150 mM MgCl2, 1 mM DTT, pH 7.5)

13

5 mL

DEPC-treated water

n/a

29.44 mL

Note: The detailed purification protocol of recombinant mouse ATE1 can be found in (Wang et al.,
2019).
40. Incubate the reactions for 5 min at 37 C.
41. Heat the reactions at 95 C for 15 min to terminate the reactions and hydrolyze the intact ArgtRNAArg or Arg-tRFArg. Note that this heating step also denatures and precipitates proteins in
the mixture, including the enzymes.
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Figure 3. Normalized Incorporation of 3H-Arg into Angiotensin II
Performed with 3H-Arg-tRNAArg and 3H-Arg-tRFArg
Data are means G SEM of three biological replicates. Reprinted
with permission from Avcilar-Kucukgoze et al. (2020).

42. Keep the tubes on ice for 20 min, then spin each at 17,000 3 g for 15 min at 20 C–22 C to pellet
the precipitated proteins. The peptides will remain in the supernatant at this step.
43. Load each supernatant onto a C18 spin column, pre-washed with 100% acetonitrile and water,
by applying the supernatant on top of the column and centrifuging the column at 110 3 g for
1 min. The peptides will bind to the column at this step. Discard the collection tube, containing
free Arg not utilized in the reaction, into radioactive waste disposal.
44. Wash the columns with 150 mL of peptide wash buffer, 0.1% (v/v) trifluoroacetic acid (TFA) in water, by centrifugation at 110 3 g for 1 min into a new collection tube. Repeat the washing step
one more time. Both collection tubes should be discarded as radioactive waste.
45. Elute the column-bound peptide from each reaction with 150 mL of peptide elution buffer, 60%
(v/v) acetonitrile, 0.1% (v/v) TFA in water, by centrifugation at 110 3 g for 1 min into a new collection tube. Repeat the elution step one more time.
46. Transfer the eluted peptide from each reaction into a scintillation vial filled with Ecoscint scintillation solution and analyze on a liquid scintillation counter.
CRITICAL: For detection of arginylation by mass spectrometry, the eluate is concentrated
by a Speedvac until 10–20 mL liquid remains. The concentrated arginylated peptide can be
directly analyzed by MALDI-TOF or LC-MS/MS.

EXPECTED OUTCOMES
Examples of tRNA preparation and generation of Arg-charged tRNA and tRF are shown in Figures 1
and 2, respectively. Outcomes of an arginylation reaction detected by scintillation counting and
MALDI-TOF mass spectrometry are shown in Figures 3 and 4, respectively. These figures illustrate
arginylation of angiotensin II – a highly efficient peptide substrate. In the case of protein substrates,
autoradiography can also be used.
In our protocol, we present two different methods for preparation of tRNAArg. While in vitro transcribed tRNA can be efficiently used in the case of arginylation, bacterially expressed tRNAs that
carry endogenous E. coli-specific post-transcriptional modifications may be more favorable for other
enzymatic reactions. In this protocol, we use RNase T2 to generate Arg-tRFArg. The efficiency of in
vitro arginylation reactions tend to vary, depending on the aminoacylation state of the tRNA (which
tends to deteriorate with storage), and can be calculated using a formula presented below. Arginylation can be qualitatively detected by MALDI-TOF, but this method should not be used for quantification (Szajli et al., 2008). The yield of arginylation can be enhanced by increasing the level of
Arg-tRFArg/Arg-tRNAArg in the arginylation reaction (step 39). Another method to increase efficiency
involves combining the RARS-mediated tRNA charging and arginylation step into a single twoenzyme reaction, where RARS continuously re-charges the Arg-tRNAArg present in the mix and
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Figure 4. MALDI-TOF Chromatogram of Angiotensin II
Arginylated Using Purified Pre-charged 13C15N-Arg-tRNAArg or
13 15
C N-Arg-tRFArg
Reprinted with permission from Avcilar-Kucukgoze et al. (2020).

thus effectively increases its availability for arginylation. The yields in such 2-enzyme reaction can be
substantially higher, and in some cases approach 100% (tested for angiotensin II arginylation (Wang
et al., 2014)). In the reaction using Arg-tRFArg, or pre-purified Arg-tRNAArg, the efficiency is lower,
likely due to the ongoing hydrolysis of the bond between Arg and tRNA/tRF, which leads to eventual
depletion of Arg-tRNA/tRF from the reaction.
An example of calculating the arginylation level:
Stock L-[2,3,4-3H]-Arg: 54.5 Ci/mmol, 1 mCi/mL (1 mCi/mL)
1 mL of stock L-[2,3,4-3H]-Arg gives 825,008 cpm.

1 mCi

825,008 cpm

X

1,547,265 cpm (for 750 pmol angiotensin
measured by a scintillation counter)

x = 1.875 mCi

54.5 mCi

1 nmol

1.875 mCi

X

x = 0.0344 nmol = 34.4 pmol

750 pmol angiotensin contains 34.4 pmol of L-[2,3,4-3H]-Arg, thereby arginylation level is 4.6%
(=34.4/750).

LIMITATIONS
Although the in vitro T7 transcription reaction provides an efficient method to synthesize a specific
tRNA, it has limitations. In order for T7 RNAP to initiate transcription, the promoter region needs
to be double-stranded, therefore filling-in the 50 overhangs of the tDNA oligonucleotides is critical. As T7 RNAP is best to initiate with a G nucleotide (G+1), RNA transcripts starting with a nucleotide other than G can be transcribed with lower efficiency. The two Gs following G + 1 significantly increase the transcription efficiency. Since the ester bond between tRNA and amino acid
is pH sensitive, it is crucial to keep the aa-tRNA in acidic conditions at all time. Therefore, an
RNase which is catalytically active in acidic pH should be used to generate aa-tRF. Otherwise,
aa-tRNA may lose its aminoacyl moiety.
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As scintillation counting usually has a background noise, even if no arginylation occurs in control
samples (the reaction without ATE1), it is difficult to detect the arginylation by scintillation counting
for an inefficient substrate. Any impurities in the individual components may affect the outcome of
the reaction. We also find that different substrates have different maximum efficiency in the arginylation reaction, with peptides and small proteins (e.g., a-synuclein) being much more efficient than
larger proteins (e.g., BSA). While we do not fully understand the reasons for these differences, we
speculate that they could be due, at least in part, to structural or sterical constraints that limit the
accessibility of the arginylation sites in a folded polypeptide chain.

TROUBLESHOOTING
Problem
The obtained cpm value is lower than expected (step 46).
Potential Solution
Purified ATE1 protein loses its enzymatic activity if it is stored at 20 C for a week. Another aliquot of
the purified ATE1 protein from 80 C should be tested. The second concern would be degradation
of tRNA due to contamination in buffer. The integrity of tRNA should be analyzed by 10% denaturing
PAGE/7.5 M urea before use.

RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Anna Kashina (akashina@upenn.edu).
Materials Availability
All materials used for this protocol are commercially available.
Data and Code Availability
This protocol does not include any datasets generated or analyzed during this study.

ACKNOWLEDGMENTS
This work was supported by NIH R35GM122505 and R01NS102435 to A.K., and R01GM126210,
AI139202, and HG010824 to Y.-M.H.

AUTHOR CONTRIBUTIONS
I.A.-K. and A.K. wrote the manuscript. H.G. and Y.-M.H. edited the paper.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
Avcilar-Kucukgoze, I., Gamper, H., Polte, C.,
Ignatova, Z., Kraetzner, R., Shtutman, M., Hou,
Y.M., Dong, D.W., and Kashina, A. (2020).
tRNA(Arg)-Derived Fragments Can Serve as
Arginine Donors for Protein Arginylation. Cell
Chem. Biol. 27, 839–849.e4.

identified in complete and draft genomes. Nucleic
Acids Res. 44, D184–D189.

terminus of RNAs transcribed by T7 RNA
polymerase. RNA 5, 1268–1272.

Gamper, H.B., Masuda, I., Frenkel-Morgenstern,
M., and Hou, Y.M. (2015). Maintenance of protein
synthesis reading frame by EF-P and m(1)G37tRNA. Nature Commun. 6, 7226.

Klein, D.J., Moore, P.B., and Steitz, T.A. (2004). The
contribution of metal ions to the structural stability
of the large ribosomal subunit. RNA 10, 1366–1379.

Campomenosi, P., Salis, S., Lindqvist, C., Mariani,
D., Nordstrom, T., Acquati, F., and Taramelli, R.
(2006). Characterization of RNASET2, the first
human member of the Rh/T2/S family of
glycoproteins. Arch Biochem. Biophys. 449, 17–26.

Hall, K.B., Sampson, J.R., Uhlenbeck, O.C., and
Redfield, A.G. (1989). Structure of an unmodified
tRNA molecule. Biochemistry 28, 5794–5801.

Chan, P.P., and Lowe, T.M. (2016). GtRNAdb 2.0: an
expanded database of transfer RNA genes

Kao, C., Zheng, M., and Rudisser, S. (1999). A
simple and efficient method to reduce
nontemplated nucleotide addition at the 3

14

STAR Protocols 1, 100207, December 18, 2020

Krupp, G. (1988). RNA synthesis: strategies for the
use of bacteriophage RNA polymerases. Gene 72,
75–89.
Liu, C., Gamper, H., Liu, H., Cooperman, B.S., and
Hou, Y.M. (2011). Potential for interdependent
development of tRNA determinants for
aminoacylation and ribosome decoding. Nature
Commun. 2, 329.

ll

Protocol
Milligan, J.F., Groebe, D.R., Witherell, G.W., and
Uhlenbeck, O.C. (1987). Oligoribonucleotide
synthesis using T7 RNA polymerase and
synthetic DNA templates. Nucleic Acids Res. 15,
8783–8798.
Sampson, J.R., and Uhlenbeck, O.C. (1988).
Biochemical and physical characterization of an
unmodified yeast phenylalanine transfer RNA
transcribed in vitro. Proc. Natl. Acad. Sci. U S A 85,
1033–1037.
Samuelsson, T., Boren, T., Johansen, T.I., and
Lustig, F. (1988). Properties of a transfer RNA

OPEN ACCESS

lacking modified nucleosides. J. Biol. Chem. 263,
13692–13699.
Serebrov, V., Vassilenko, K., Kholod, N., Gross, H.J.,
and Kisselev, L. (1998). Mg2+ binding and structural
stability of mature and in vitro synthesized
unmodified Escherichia coli tRNAPhe. Nucleic
Acids Res. 26, 2723–2728.
Szajli, E., Feher, T., and Medzihradszky, K.F. (2008).
Investigating the quantitative nature of MALDITOF MS. Mol. Cell. Proteomics 7, 2410–2418.
Thorn, A., Steinfeld, R., Ziegenbein, M., Grapp, M.,
Hsiao, H.H., Urlaub, H., Sheldrick, G.M., Gartner, J.,

and Kratzner, R. (2012). Structure and activity of the
only human RNase T2. Nucleic Acids Res. 40, 8733–
8742.
Wang, J., Han, X., Wong, C.C., Cheng, H., Aslanian,
A., Xu, T., Leavis, P., Roder, H., Hedstrom, L., Yates,
J.R., 3rd, et al. (2014). Arginyltransferase ATE1
catalyzes midchain arginylation of proteins at
side chain carboxylates in vivo. Chem. Biol. 21,
331–337.
Wang, J., Yates, J.R., 3rd, and Kashina, A. (2019).
Biochemical analysis of protein arginylation.
Methods Enzymol. 626, 89–113.

STAR Protocols 1, 100207, December 18, 2020

15

